Drugs / 10-1074-LS-J
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06031272 | May 2024 → Oct 2025 overdue | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04173819 | Jan 2019 → Sep 2023 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 10-1074-LS-J | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04173819 ↗ |
| Modality | Monoclonal antibody | “two broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4 binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3...” NCT04173819 ↗ |
| Route | Intravenous | “co-administered subcutaneously or intravenously” NCT04173819 ↗ |
| Route | Subcutaneous | “co-administered subcutaneously or intravenously” NCT04173819 ↗ |